http://www.nasdaq.com/article/thora...ll-on-growing-headwinds-analyst-blog-cm413451
The revenue drop was primarily due to the decline in HeartMate II sales, partially offset by continued double-digit revenue growth in the CentriMag business. Third-quarter revenues of $105.8 million also lagged the Zacks Consensus Estimate of $108 million.
The company also slashed its adjusted earnings and revenue guidance owing to lower assumptions for HeartMate II product line on the back of near-term challenges. Thoratec anticipates higher operating expenses in the fourth quarter of 2014 due to accelerated clinical trial activity, targeted commercial investments, and product development project expenses.
